explore -WSS

explore

author：hotspot 2025-09-30 14:08:45 - browse：93392

Three Wegovy injection pens in a row — first opinion coverage from STAT — Adobe

Novo Nordisk will test whether its GLP-1 drugs can help people with alcohol-associated liver disease, and, as part of that, will study if the treatments will change the amount of alcohol people drink.

This appears to be the first time the company is getting involved in research to see if the booming class of GLP-1 diabetes and obesity drugs can affect substance consumption, a question that academic researchers have been probing but the pharmaceutical industry has so far avoided.

The nine-month study will try three drugs alone and in combinations against placebo. The primary outcome being tested is change in liver scarring, or fibrosis, and one of the secondary outcomes is changes in alcohol consumption. The news of the study was first reported by Bloomberg.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Caregivers of transplant patients call for more support, training

hotspot

leisure time

WSS

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

New Medicare drug pricing powers could soon be upended in court

Heart attack and stroke risk calculators need revising

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Generative AI mines health records to identify patients’ social needs

Drug repurposing or repositioning? The language matters

explore

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

leisure time

Wildfire smoke exposes gaps in outdoor worker protections

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

Bright Health sells Medicare Advantage business to Molina

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

Malaria cases in Florida and Texas: Here’s what you need to know

Designating disabled people as health disparity population is crucial

Hollywood unions extend contract negotiations for actors

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Anesthesiologist group: stop taking Ozempic before surgery

Continuity nursing helped my family in our darkest PICU moments

hotspot

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

DeSantis can now import cheaper drugs. But will Biden get credit?

Doulas covered by Medicaid under New York's new plan

Risky weight loss products often used by teens globally, per study

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

The nurse manager staffing crisis is hurting patients

hotspot

leisure time

focus

focus